Collegium Pharmaceutical acquires Corium Therapeutics

Collegium Pharmaceutical agreed to acquire Corium Therapeutics. Reported deal value: $650M. Status: Pending. Sector: Biopharmaceutical. Target headquarters context: Location not specified.

This page summarizes publicly available information about the transaction as of 2026-03-19. Figures and status may change as filings and press coverage update.

Collegium Pharmaceutical , Inc. and Corium Therapeutics Holdings , LLC , today announced a definitive agreement pursuant to which Collegium will acquire AZSTARYS for $650 million in cash with the potential for additional milestone payments up to $ 13 5 million depending on future commercial and regulatory milestones